Skip to main content

Annabelle Parent

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Annabelle Parent

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, Malalties neurodegeneratives , Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Malalties neurodegeneratives , Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

Mecanismos moleculares de neurodegeneración ligada a la neuromelanina en la enfermedad de Parkinson y envejecimiento cerebral

IP: Miquel Vila Bover
Collaborators: Thais Cuadros Arasa, Helena Xicoy Cortada, Marta González Sepúlveda, Annabelle Parent
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 332750
Reference: PID2020-116339RB-I00
Duration: 01/09/2021 - 31/08/2024

Ministerio de Ciencia

Modulation of age-dependent neuromelanin accumulation as a novel therapeutic strategy for Parkinson’s disease and brain aging

IP: Miquel Vila Bover
Collaborators: Ariadna Laguna Tuset, Thais Cuadros Arasa, Marta González Sepúlveda, Annabelle Parent
Funding agency: Fundació "La Caixa"
Funding: 466004
Reference: FBLC/HR17-00513/VILA
Duration: 01/09/2018 - 05/01/2022

Disfunción mitocondrial en la enfermedad de Parkinson: papel de la dinámica mitocondrial

IP: -
Collaborators: Annabelle Parent
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 114950
Reference: SAF2013-43158-R
Duration: 01/01/2014 - 31/12/2016

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Anna Sanjuan Viaplana

Anna Sanjuan Viaplana

Medium Grade Technician
Statistics and Bioinformatics Unit (UEB)
Digital Transformation Directorate
Read more
Arranz Figols, Anna

Arranz Figols, Anna

Shock, Organ Dysfunction and Resuscitation
Read more
Joan Compte Barrón

Joan Compte Barrón

Predoctoral researcher
Neurodegenerative Diseases
Read more
Bragulat Arevalo, Mireia

Bragulat Arevalo, Mireia

Research technician
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.